Analysts think SLNO stock price could increase by 39%
May 10, 2025, 11:25 AM
-1.71%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
11 analysts think SLNO stock price will increase by 39.40%. The current median analyst target is $107.10 compared to a current stock price of $76.83. The lowest analysts target is $81.81 and the highest analyst target is $152.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.